Vincent Liptak, J.D., Ph.D., MBA
Executive Vice President and General Counsel
Vincent Liptak, J.D., Ph.D., MBA is executive vice president and general counsel at BlossomHill Therapeutics. Dr. Liptak has more than 20 years of experience in the legal profession. Prior to joining BlossomHill, he was a partner at Barnes & Thornburg, LLP, serving as outside counsel for many chemical and life sciences clients. While at Barnes & Thornburg, Dr. Liptak was co-chair of the firm’s Life Sciences Practice Group. With pharmaceutical patents as his practice focus, he has written hundreds of patents covering many aspects of pharmaceutical compounds, including patents covering several FDA-approved products. He has worked with BlossomHill’s Scientific Founder, President, and CEO Dr. J. Jean Cui, for nearly 20 years, beginning as colleagues at Pfizer, Inc. in La Jolla, Calif. Throughout his career, Dr. Liptak has written patents that cover crizotinib (XALKORI®), lorlatinib (LOBRENA®), repotrectinib (AUGTYRO®) and elzovantinib, as well as other compounds discovered by Dr. Cui and her colleagues at Pfizer, Turning Point Therapeutics, Inc. and BlossomHill.
He received hisMaster of Science and doctorate from The University of Chicago, a J.D. and Master of Business Administration from the University of San Diego and a Bachelor of Science with a double major in chemistry and mathematics from Loyola University Chicago. Before entering the legal profession, Dr. Liptak was a postdoc in Prof. Dennis Dougherty’s laboratory at the California Institute of Technology in Pasadena, Calif. He is registered to practice law in California and Indiana and is registered to practice before the United States Patent and Trademark Office.